51³Ô¹ÏÍø

Montreal – November 6, 2025 | The DNA to RNA (D2R) initiative at 51³Ô¹ÏÍø is proud to announce the recipients of the second cycle of the Foundational and Research in Motion (RIM) funding programs.

From common diseases affecting millions, such as lung cancer, to rare disorders like lipodystrophy, this investment of over 5.3 million dollars reflects D2R’s commitment to advancing bold ideas and fostering interdisciplinary collaboration across the discovery-to-implementation spectrum.

The call for applications for Cycle 2 of D2R's Foundational and Research in Motion programs (RIM) integrated two previously separate funding programs into a single, unified call. These programs supports high-risk research and development with potential for high impact in RNA therapeutics, fostering breakthrough innovations and interdisciplinary collaboration. This funding opportunity provides researchers with the flexibility to explore novel ideas and develop cutting-edge solutions that have the potential to lead to commercialization or clinical application. 

The evaluation of the 59 applications received was conducted in two stages: (1) a scientific merit review by external peer reviewers and (2) a strategic alignment review by the Strategic Alignment Review Committee which resulted in 28 projects being successfully funded. The awarded projects are led by Principal and Co-Investigators from 51³Ô¹ÏÍø, as well as D2R partner institutions—the Université de Sherbrooke and the University of British Columbia. Additionally, 3.9 million dollars was allocated to support trainees to work and learn alongside all the funded P.Is at each of these academic institutions.